CNS Pharmaceuticals, Inc. · NASDAQ:CNSP
CNS Pharmaceuticals — Investor Presentation (October 2024)
17 slides from CNS Pharmaceuticals's investor presentation, October 2024
Slide 1: NASDAQ: CNSP October 2024
NASDAQ: CNSP October 2024 1
Slide 2: Forward Looking Statements
2 Forward Looking Statements This presentation incorporates information from materials filed with the SEC and contains forward-looking statements. All statements contained herein other than statements of historical fact, including statements regarding our future results of operations and financial p
Slide 3: Company Overview
Company Overview Lead Program: Berubicin, a Novel Anthracycline • First drug of its kind to appear to cross the blood brain barrier • Fully-enrolled designed-to-be-pivotal clinical trial with top-line data 1st half 2025 • No evidence of cardiotoxicity in hundreds of patients • Developed at MD Anders
Slide 4: A Focused and Targeted CNS Oncology Pipeline
A Focused and Targeted CNS Oncology Pipeline Program Indications Preclinical Phase 1 Phase 2 Phase 3 Highlights Glioblastoma • Study Fully Enrolled Berubicin Multiforme (GBM) Potentially Pivotal • Topline Data Expected H1 2025 • Recently in-licensed Glioblastoma TPI 287 Multiforme (GBM) • Plan to en
Slide 5: Glioblastoma Multiforme (GBM)
5 Glioblastoma Multiforme (GBM) Most Aggressive, Deadly and Currently Incurable Brain Cancer 12 – 18 MONTHS >50,000 $1B+ New cases in the 8 Major Global annual sales TMZ Average life expectancy1 Only approved first line Markets2 each year3 drug (off patent 12 years) The Blood Brain Barrier Limits th
Slide 6: Berubicin: Targeted Chemotherapy Results
Berubicin: Targeted Chemotherapy Results Complete Response at 6-month Post Treatment* 44% Two partial responses of subjects demonstrated “stable with up to80% tumor shrinkage disease or better” Extremely well DURABLE COMPLETE tolerated with a good RESPONSE (CR) - One safety profile (no off- subject
Slide 7: Phase 2/3 Clinical Trial Data Expected 1st Half 2025
Phase 2/3 Clinical Trial De-Risked Data Expected 1 Half 2025 st ✓45 Centers in 8 countries Fully Enrolled ✓All 252 patients dosed 252 Subjects ✓All drug supply in hand ✓Pivotal endpoint 6-12 months Randomized: 2:1 BERUBICIN LOMUSTINE 168 subjects 84 subjects Independent Data Safety Monitoring 7.1 mg
Slide 8: A Much Bigger Story beyond GBM
8 A Much Bigger Story beyond GBM EST. U.S. NEW INDICATION PATIENT POPULATION COMMENTS PATIENTS ANNUALLY Primary Brain Tumors Relapsed High Grade 15,000 Existing data in this population Gliomas $2.3B Market in 2022 High Grade Gliomas are the most common malignant brain High Grade Gliomas in Pediatric
Slide 9: Intellectual Property
Intellectual Property Orphan Drug Orphan Drug Designation New gives marketing exclusivity in US market Chemical Entity for 7-years from approval CNS is exploring potential Upcoming filing after final new patent filings covering data in the E.U. for Orphan manufacturing and other Drug Designation may
Slide 10: TPI 287
TPI 287 Late Stage, Novel Blood Brain Barrier Permeable Abeotaxane for Treatment of Brain Malignancies 10
Slide 11: TPI 287: Targeting GBM
TPI 287: Targeting GBM Has Shown Efficacy Data and Safety Profile in Prior Trials Studied in Over 350 Patients to Date • Evaluated in multiple Phase 1 and Phase 2 studies with favorable efficacy data in GBM in combination with bevacizumab • 60% overall response rate (3 CR; 9 PR) • 96% disease contro
Slide 12: Readily Penetrates the Blood Brain Barrier in Animal Models
Readily Penetrates the Blood Brain Barrier in Animal Models 12
Slide 13: Improved GBM Survival In Combination with Bevacizumab
Improved GBM Survival In Combination with Bevacizumab * Graphs represent aggregate data from multiple studies 14
Slide 14: Management Team
Management Team John M. Climaco, Esq PRESIDENT & CHIEF EXECUTIVE OFFICER Twenty-one years experience managing the operations, strategies and finances of public and private lifescience companies. Christopher S. Downs, CPA CHIEF FINANCIAL OFFICER Nearly 20 years of finance and investment banking exper
Slide 15: Proven Execution and Milestones
Proven Execution and Milestones Berubicin Development Program Patient Dosing in Initiated Potentially Potentially Pivotal Approval from Pivotal Trial Completion of Orphan Drug Pivotal Global Berubicin Study Expected France EC and CA Expansion into Enrollment of Planned Designation Trial for GBM to C
Slide 16: Investment Highlights
Investment Highlights Lead Program: Berubicin, a Novel Anthracycline • First drug of its kind to appear to cross the blood brain barrier • Fully-enrolled designed-to-be-pivotal clinical trial with top-line data 1st half 2025 • No evidence of cardiotoxicity in hundreds of patients • Developed at MD A
Slide 17: NASDAQ: CNSP Investor & Media Relations
Investor & Media Relations: JTC Team, LLC NASDAQ: CNSP Jenene Thomas 908.824.0775 CNSP@JTCIR.com 18
CNS Pharmaceuticals — Investor Presentation (October 2024) on 6ix